8-K: Humana Reaffirms 2026 EPS Guidance

Humana Inc. reaffirms its full-year 2026 diluted earnings per common share guidance of at least $6.52 and adjusted earnings per common share of at least $9.00.

Summary

• Humana Inc. is reaffirming its previously issued guidance for the fiscal year ending December 31, 2026 (FY 2026).
• The company expects diluted earnings per common share (EPS) to be at least $6.52.
• Adjusted earnings per common share (Adjusted EPS) are projected to be at least $9.00 for FY 2026.
• This guidance is consistent with the company's press release dated July 29, 2026.
• Humana will not comment on 2027 Medicare Advantage (MA) Star Ratings (Bonus Year 2028) until the Centers for Medicare and Medicaid Services (CMS) releases final data in October.
• The company uses Adjusted EPS, a non-GAAP measure, to provide a more comprehensive perspective on core operating performance.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive update, primarily focused on reaffirming existing financial guidance rather than introducing new information or significant changes.

Positives

• Reaffirmation of strong FY 2026 Adjusted EPS guidance of at least $9.00.
• Reaffirmation of FY 2026 GAAP EPS guidance of at least $6.52.
• Management's belief that Adjusted EPS provides a comprehensive perspective on core operating performance.

Negatives

• Potential changes to FY 2026 GAAP EPS guidance are expected due to ongoing value creation and strategic initiatives, though specific impacts are not detailed.
• The company is deferring comments on 2027 Medicare Advantage Star Ratings until October, indicating potential future uncertainty or sensitivity around this metric.

Risks

• Forward-looking statements are subject to risks, uncertainties, and assumptions, including those detailed in the company's SEC filings.
• The company's Adjusted EPS is subject to inherent limitations and may differ from measures used by other companies.

Future Outlook

Humana is reaffirming its FY 2026 guidance for both GAAP EPS (at least $6.52) and Adjusted EPS (at least $9.00). The company does not expect changes to its Adjusted EPS guidance but anticipates potential changes to its GAAP EPS guidance due to ongoing strategic initiatives.

Management Comments

• Management believes that Adjusted (non-GAAP) EPS, when presented with GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company's core operating performance over time.
• Management uses Adjusted (non-GAAP) EPS as a consistent indicator of the Company's core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation.

Industry Context

StockSavvy.ai notes that reaffirming guidance during investor meetings is a common practice for companies to maintain investor confidence. The deferral of comments on Medicare Advantage Star Ratings is significant, as these ratings directly impact bonus payments and are a key performance indicator for health insurers operating in government programs.

Stakeholder Impact

• Shareholders: Reaffirmation of EPS guidance provides clarity and stability, potentially supporting investor confidence.
• Employees: Management's use of Adjusted EPS for incentive compensation highlights its importance in performance evaluation.
• Government Programs (Medicare Advantage): The deferral of comments on Star Ratings suggests ongoing evaluation and potential future impact on bonus revenue.

Next Steps

• Humana senior management will meet with investors and analysts between September 1, 2026, and September 30, 2026.
• The Centers for Medicare and Medicaid Services (CMS) is expected to release final 2027 MA Star Ratings data in October.

Key Dates

Recommendation

The filing is a routine reaffirmation of existing guidance and does not introduce new information that would warrant a change in investment strategy. While the guidance is positive, it is not a significant upgrade or new development.

Keywords

Earnings Per Share, Guidance, Medicare Advantage, Financial Performance, Healthcare, Investor Meetings